nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—DDC—Dopamine metabolism—TYR—skin cancer	0.0751	0.338	CbGpPWpGaD
Methyldopa—COMT—Dopamine metabolism—TYR—skin cancer	0.0667	0.3	CbGpPWpGaD
Methyldopa—VIIth nerve paralysis—Vemurafenib—skin cancer	0.0242	0.0358	CcSEcCtD
Methyldopa—DDC—nerve—skin cancer	0.0207	0.211	CbGeAlD
Methyldopa—Amenorrhoea—Vismodegib—skin cancer	0.0183	0.0271	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—GLI2—skin cancer	0.0167	0.0753	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—GLI1—skin cancer	0.0157	0.0708	CbGpPWpGaD
Methyldopa—COMT—hair follicle—skin cancer	0.0115	0.117	CbGeAlD
Methyldopa—DDC—Dopaminergic Neurogenesis—SHH—skin cancer	0.0114	0.0512	CbGpPWpGaD
Methyldopa—Pericarditis—Fluorouracil—skin cancer	0.0108	0.016	CcSEcCtD
Methyldopa—Breast disorder—Vismodegib—skin cancer	0.0105	0.0156	CcSEcCtD
Methyldopa—Parkinsonism—Fluorouracil—skin cancer	0.0103	0.0152	CcSEcCtD
Methyldopa—Vasculitis—Vemurafenib—skin cancer	0.0102	0.015	CcSEcCtD
Methyldopa—Tenderness—Imiquimod—skin cancer	0.0097	0.0144	CcSEcCtD
Methyldopa—Connective tissue disorder—Vismodegib—skin cancer	0.00793	0.0117	CcSEcCtD
Methyldopa—COMT—nipple—skin cancer	0.00779	0.0794	CbGeAlD
Methyldopa—Tenderness—Bleomycin—skin cancer	0.00689	0.0102	CcSEcCtD
Methyldopa—Eczema—Imiquimod—skin cancer	0.00684	0.0101	CcSEcCtD
Methyldopa—Nasal congestion—Imiquimod—skin cancer	0.00675	0.00998	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Vemurafenib—skin cancer	0.00649	0.0096	CcSEcCtD
Methyldopa—Eosinophilia—Vemurafenib—skin cancer	0.00617	0.00912	CcSEcCtD
Methyldopa—Endocrine disorder—Temozolomide—skin cancer	0.00612	0.00906	CcSEcCtD
Methyldopa—Liver injury—Temozolomide—skin cancer	0.00603	0.00892	CcSEcCtD
Methyldopa—Arthralgia—Vismodegib—skin cancer	0.00598	0.00885	CcSEcCtD
Methyldopa—Myalgia—Vismodegib—skin cancer	0.00598	0.00885	CcSEcCtD
Methyldopa—Foetor hepaticus—Docetaxel—skin cancer	0.00595	0.0088	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00594	0.00879	CcSEcCtD
Methyldopa—SLC15A1—epithelium—skin cancer	0.00589	0.0601	CbGeAlD
Methyldopa—DDC—female reproductive system—skin cancer	0.00589	0.06	CbGeAlD
Methyldopa—Amenorrhoea—Temozolomide—skin cancer	0.00577	0.00854	CcSEcCtD
Methyldopa—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00565	0.0254	CbGpPWpGaD
Methyldopa—Nervous system disorder—Vismodegib—skin cancer	0.00562	0.00832	CcSEcCtD
Methyldopa—Skin disorder—Vismodegib—skin cancer	0.00557	0.00824	CcSEcCtD
Methyldopa—Breast disorder—Imiquimod—skin cancer	0.00555	0.00822	CcSEcCtD
Methyldopa—Infestation NOS—Vemurafenib—skin cancer	0.00555	0.00822	CcSEcCtD
Methyldopa—Infestation—Vemurafenib—skin cancer	0.00555	0.00822	CcSEcCtD
Methyldopa—Tenderness—Fluorouracil—skin cancer	0.00536	0.00793	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00522	0.00773	CcSEcCtD
Methyldopa—SLC15A1—mammalian vulva—skin cancer	0.00511	0.0521	CbGeAlD
Methyldopa—Pancytopenia—Imiquimod—skin cancer	0.00504	0.00746	CcSEcCtD
Methyldopa—COMT—skin of body—skin cancer	0.00499	0.0508	CbGeAlD
Methyldopa—Liver disorder—Docetaxel—skin cancer	0.00495	0.00732	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vismodegib—skin cancer	0.00495	0.00732	CcSEcCtD
Methyldopa—DDC—head—skin cancer	0.00492	0.0501	CbGeAlD
Methyldopa—Constipation—Vismodegib—skin cancer	0.0049	0.00725	CcSEcCtD
Methyldopa—Connective tissue disorder—Vemurafenib—skin cancer	0.0049	0.00725	CcSEcCtD
Methyldopa—Erectile dysfunction—Imiquimod—skin cancer	0.00489	0.00724	CcSEcCtD
Methyldopa—Infestation—Imiquimod—skin cancer	0.00474	0.00701	CcSEcCtD
Methyldopa—Infestation NOS—Imiquimod—skin cancer	0.00474	0.00701	CcSEcCtD
Methyldopa—Cardiac disorder—Vemurafenib—skin cancer	0.00463	0.00685	CcSEcCtD
Methyldopa—COMT—mammalian vulva—skin cancer	0.00455	0.0463	CbGeAlD
Methyldopa—Angiopathy—Vemurafenib—skin cancer	0.00452	0.00669	CcSEcCtD
Methyldopa—Mediastinal disorder—Vemurafenib—skin cancer	0.00449	0.00665	CcSEcCtD
Methyldopa—Hepatobiliary disease—Imiquimod—skin cancer	0.00448	0.00663	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—NKX2-1—skin cancer	0.0043	0.0193	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Imiquimod—skin cancer	0.00418	0.00618	CcSEcCtD
Methyldopa—Asthenia—Vismodegib—skin cancer	0.00411	0.00609	CcSEcCtD
Methyldopa—Nasal congestion—Temozolomide—skin cancer	0.00404	0.00598	CcSEcCtD
Methyldopa—ADRA2A—nipple—skin cancer	0.00397	0.0404	CbGeAlD
Methyldopa—Diarrhoea—Vismodegib—skin cancer	0.00392	0.0058	CcSEcCtD
Methyldopa—COMT—female reproductive system—skin cancer	0.00389	0.0397	CbGeAlD
Methyldopa—Angiopathy—Imiquimod—skin cancer	0.00386	0.00571	CcSEcCtD
Methyldopa—Amenorrhoea—Docetaxel—skin cancer	0.00384	0.00568	CcSEcCtD
Methyldopa—Mediastinal disorder—Imiquimod—skin cancer	0.00383	0.00567	CcSEcCtD
Methyldopa—Liver function test abnormal—Dactinomycin—skin cancer	0.00376	0.00556	CcSEcCtD
Methyldopa—Mental disorder—Imiquimod—skin cancer	0.00373	0.00551	CcSEcCtD
Methyldopa—Arthralgia—Vemurafenib—skin cancer	0.0037	0.00547	CcSEcCtD
Methyldopa—Myalgia—Vemurafenib—skin cancer	0.0037	0.00547	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00367	0.00543	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Dactinomycin—skin cancer	0.00367	0.00543	CcSEcCtD
Methyldopa—Vomiting—Vismodegib—skin cancer	0.00365	0.00539	CcSEcCtD
Methyldopa—Rash—Vismodegib—skin cancer	0.00362	0.00535	CcSEcCtD
Methyldopa—Dermatitis—Vismodegib—skin cancer	0.00361	0.00534	CcSEcCtD
Methyldopa—Pancytopenia—Bleomycin—skin cancer	0.00358	0.0053	CcSEcCtD
Methyldopa—Infection—Vemurafenib—skin cancer	0.00352	0.00521	CcSEcCtD
Methyldopa—Nervous system disorder—Vemurafenib—skin cancer	0.00347	0.00514	CcSEcCtD
Methyldopa—DDC—lymph node—skin cancer	0.00345	0.0351	CbGeAlD
Methyldopa—Skin disorder—Vemurafenib—skin cancer	0.00344	0.00509	CcSEcCtD
Methyldopa—Nausea—Vismodegib—skin cancer	0.00341	0.00504	CcSEcCtD
Methyldopa—Hepatocellular injury—Docetaxel—skin cancer	0.00337	0.00499	CcSEcCtD
Methyldopa—Pancytopenia—Dactinomycin—skin cancer	0.00334	0.00495	CcSEcCtD
Methyldopa—Breast disorder—Temozolomide—skin cancer	0.00333	0.00492	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Temozolomide—skin cancer	0.00332	0.00491	CcSEcCtD
Methyldopa—COMT—head—skin cancer	0.00325	0.0332	CbGeAlD
Methyldopa—Colitis—Docetaxel—skin cancer	0.00324	0.00479	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00323	0.00477	CcSEcCtD
Methyldopa—Abdominal distension—Temozolomide—skin cancer	0.0032	0.00474	CcSEcCtD
Methyldopa—Arthralgia—Imiquimod—skin cancer	0.00315	0.00466	CcSEcCtD
Methyldopa—Myalgia—Imiquimod—skin cancer	0.00315	0.00466	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00313	0.00463	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00306	0.00452	CcSEcCtD
Methyldopa—Constipation—Vemurafenib—skin cancer	0.00303	0.00448	CcSEcCtD
Methyldopa—Pancytopenia—Temozolomide—skin cancer	0.00302	0.00447	CcSEcCtD
Methyldopa—Oedema—Imiquimod—skin cancer	0.00302	0.00447	CcSEcCtD
Methyldopa—Lightheadedness—Docetaxel—skin cancer	0.00302	0.00447	CcSEcCtD
Methyldopa—Infection—Imiquimod—skin cancer	0.003	0.00444	CcSEcCtD
Methyldopa—Nervous system disorder—Imiquimod—skin cancer	0.00296	0.00438	CcSEcCtD
Methyldopa—Skin disorder—Imiquimod—skin cancer	0.00293	0.00434	CcSEcCtD
Methyldopa—Erectile dysfunction—Temozolomide—skin cancer	0.00293	0.00434	CcSEcCtD
Methyldopa—Agranulocytosis—Dactinomycin—skin cancer	0.00293	0.00433	CcSEcCtD
Methyldopa—Eosinophilia—Fluorouracil—skin cancer	0.0029	0.0043	CcSEcCtD
Methyldopa—Weight increased—Temozolomide—skin cancer	0.0029	0.00429	CcSEcCtD
Methyldopa—Angina pectoris—Fluorouracil—skin cancer	0.00286	0.00423	CcSEcCtD
Methyldopa—Infestation NOS—Temozolomide—skin cancer	0.00284	0.0042	CcSEcCtD
Methyldopa—Infestation—Temozolomide—skin cancer	0.00284	0.0042	CcSEcCtD
Methyldopa—Hepatitis—Dactinomycin—skin cancer	0.00282	0.00417	CcSEcCtD
Methyldopa—ADRA2A—connective tissue—skin cancer	0.00281	0.0287	CbGeAlD
Methyldopa—Body temperature increased—Vemurafenib—skin cancer	0.0028	0.00414	CcSEcCtD
Methyldopa—Pancytopenia—Fluorouracil—skin cancer	0.00279	0.00412	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00275	0.00407	CcSEcCtD
Methyldopa—Paraesthesia—Imiquimod—skin cancer	0.00271	0.00401	CcSEcCtD
Methyldopa—Cardiac failure congestive—Docetaxel—skin cancer	0.0027	0.004	CcSEcCtD
Methyldopa—Hepatobiliary disease—Temozolomide—skin cancer	0.00268	0.00397	CcSEcCtD
Methyldopa—Infestation NOS—Fluorouracil—skin cancer	0.00262	0.00387	CcSEcCtD
Methyldopa—Infestation—Fluorouracil—skin cancer	0.00262	0.00387	CcSEcCtD
Methyldopa—Hypersensitivity—Vemurafenib—skin cancer	0.00261	0.00386	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Imiquimod—skin cancer	0.00261	0.00386	CcSEcCtD
Methyldopa—Hepatitis—Temozolomide—skin cancer	0.00255	0.00377	CcSEcCtD
Methyldopa—Asthenia—Vemurafenib—skin cancer	0.00254	0.00376	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00253	0.0114	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Temozolomide—skin cancer	0.0025	0.0037	CcSEcCtD
Methyldopa—Agranulocytosis—Fluorouracil—skin cancer	0.00244	0.00361	CcSEcCtD
Methyldopa—Diarrhoea—Vemurafenib—skin cancer	0.00242	0.00359	CcSEcCtD
Methyldopa—Body temperature increased—Imiquimod—skin cancer	0.00239	0.00353	CcSEcCtD
Methyldopa—Cardiac disorder—Temozolomide—skin cancer	0.00236	0.0035	CcSEcCtD
Methyldopa—Leukopenia—Bleomycin—skin cancer	0.00235	0.00348	CcSEcCtD
Methyldopa—Dizziness—Vemurafenib—skin cancer	0.00234	0.00347	CcSEcCtD
Methyldopa—ADRA2A—mammalian vulva—skin cancer	0.00232	0.0236	CbGeAlD
Methyldopa—Angiopathy—Temozolomide—skin cancer	0.00231	0.00342	CcSEcCtD
Methyldopa—Mediastinal disorder—Temozolomide—skin cancer	0.0023	0.0034	CcSEcCtD
Methyldopa—COMT—lymph node—skin cancer	0.00228	0.0232	CbGeAlD
Methyldopa—Liver function test abnormal—Docetaxel—skin cancer	0.00226	0.00335	CcSEcCtD
Methyldopa—Vomiting—Vemurafenib—skin cancer	0.00225	0.00333	CcSEcCtD
Methyldopa—Myalgia—Bleomycin—skin cancer	0.00224	0.00331	CcSEcCtD
Methyldopa—Orthostatic hypotension—Docetaxel—skin cancer	0.00224	0.00331	CcSEcCtD
Methyldopa—Rash—Vemurafenib—skin cancer	0.00223	0.0033	CcSEcCtD
Methyldopa—Mental disorder—Temozolomide—skin cancer	0.00223	0.0033	CcSEcCtD
Methyldopa—Dermatitis—Vemurafenib—skin cancer	0.00223	0.0033	CcSEcCtD
Methyldopa—Hypersensitivity—Imiquimod—skin cancer	0.00223	0.00329	CcSEcCtD
Methyldopa—Headache—Vemurafenib—skin cancer	0.00222	0.00328	CcSEcCtD
Methyldopa—Breast disorder—Docetaxel—skin cancer	0.00221	0.00327	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Docetaxel—skin cancer	0.00221	0.00326	CcSEcCtD
Methyldopa—Leukopenia—Dactinomycin—skin cancer	0.0022	0.00325	CcSEcCtD
Methyldopa—Asthenia—Imiquimod—skin cancer	0.00217	0.00321	CcSEcCtD
Methyldopa—Oedema—Bleomycin—skin cancer	0.00215	0.00317	CcSEcCtD
Methyldopa—Infection—Bleomycin—skin cancer	0.00213	0.00315	CcSEcCtD
Methyldopa—Nausea—Vemurafenib—skin cancer	0.0021	0.00311	CcSEcCtD
Methyldopa—Thrombocytopenia—Bleomycin—skin cancer	0.0021	0.00311	CcSEcCtD
Methyldopa—Myalgia—Dactinomycin—skin cancer	0.00209	0.00309	CcSEcCtD
Methyldopa—Diarrhoea—Imiquimod—skin cancer	0.00207	0.00306	CcSEcCtD
Methyldopa—Angina pectoris—Docetaxel—skin cancer	0.00206	0.00305	CcSEcCtD
Methyldopa—Pancytopenia—Docetaxel—skin cancer	0.00201	0.00297	CcSEcCtD
Methyldopa—Oedema—Dactinomycin—skin cancer	0.002	0.00296	CcSEcCtD
Methyldopa—Dizziness—Imiquimod—skin cancer	0.002	0.00296	CcSEcCtD
Methyldopa—Infection—Dactinomycin—skin cancer	0.00199	0.00294	CcSEcCtD
Methyldopa—Leukopenia—Temozolomide—skin cancer	0.00199	0.00294	CcSEcCtD
Methyldopa—ADRA2A—female reproductive system—skin cancer	0.00198	0.0202	CbGeAlD
Methyldopa—Aminosalicylic Acid—PTGS2—skin cancer	0.00197	0.561	CrCbGaD
Methyldopa—Thrombocytopenia—Dactinomycin—skin cancer	0.00196	0.0029	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00196	0.00289	CcSEcCtD
Methyldopa—Paraesthesia—Bleomycin—skin cancer	0.00193	0.00285	CcSEcCtD
Methyldopa—Weight increased—Docetaxel—skin cancer	0.00193	0.00285	CcSEcCtD
Methyldopa—Vomiting—Imiquimod—skin cancer	0.00192	0.00284	CcSEcCtD
Methyldopa—Rash—Imiquimod—skin cancer	0.0019	0.00282	CcSEcCtD
Methyldopa—Dermatitis—Imiquimod—skin cancer	0.0019	0.00282	CcSEcCtD
Methyldopa—Headache—Imiquimod—skin cancer	0.00189	0.0028	CcSEcCtD
Methyldopa—Arthralgia—Temozolomide—skin cancer	0.00189	0.00279	CcSEcCtD
Methyldopa—Myalgia—Temozolomide—skin cancer	0.00189	0.00279	CcSEcCtD
Methyldopa—Infestation NOS—Docetaxel—skin cancer	0.00189	0.00279	CcSEcCtD
Methyldopa—Infestation—Docetaxel—skin cancer	0.00189	0.00279	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00188	0.00277	CcSEcCtD
Methyldopa—Jaundice—Docetaxel—skin cancer	0.00184	0.00272	CcSEcCtD
Methyldopa—Leukopenia—Fluorouracil—skin cancer	0.00183	0.00271	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00182	0.0027	CcSEcCtD
Methyldopa—Oedema—Temozolomide—skin cancer	0.00181	0.00268	CcSEcCtD
Methyldopa—Infection—Temozolomide—skin cancer	0.0018	0.00266	CcSEcCtD
Methyldopa—Nausea—Imiquimod—skin cancer	0.00179	0.00265	CcSEcCtD
Methyldopa—Hepatobiliary disease—Docetaxel—skin cancer	0.00179	0.00264	CcSEcCtD
Methyldopa—Nervous system disorder—Temozolomide—skin cancer	0.00178	0.00263	CcSEcCtD
Methyldopa—Thrombocytopenia—Temozolomide—skin cancer	0.00177	0.00262	CcSEcCtD
Methyldopa—Agranulocytosis—Docetaxel—skin cancer	0.00176	0.00261	CcSEcCtD
Methyldopa—Skin disorder—Temozolomide—skin cancer	0.00176	0.0026	CcSEcCtD
Methyldopa—Myalgia—Fluorouracil—skin cancer	0.00174	0.00257	CcSEcCtD
Methyldopa—Body temperature increased—Bleomycin—skin cancer	0.0017	0.00251	CcSEcCtD
Methyldopa—Hepatitis—Docetaxel—skin cancer	0.00169	0.00251	CcSEcCtD
Methyldopa—Oedema—Fluorouracil—skin cancer	0.00167	0.00247	CcSEcCtD
Methyldopa—Connective tissue disorder—Docetaxel—skin cancer	0.00167	0.00246	CcSEcCtD
Methyldopa—Infection—Fluorouracil—skin cancer	0.00166	0.00245	CcSEcCtD
Methyldopa—ADRA2A—head—skin cancer	0.00166	0.0169	CbGeAlD
Methyldopa—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00165	0.00244	CcSEcCtD
Methyldopa—Nervous system disorder—Fluorouracil—skin cancer	0.00164	0.00242	CcSEcCtD
Methyldopa—Thrombocytopenia—Fluorouracil—skin cancer	0.00163	0.00242	CcSEcCtD
Methyldopa—Paraesthesia—Temozolomide—skin cancer	0.00163	0.0024	CcSEcCtD
Methyldopa—Body temperature increased—Dactinomycin—skin cancer	0.00158	0.00234	CcSEcCtD
Methyldopa—Hypersensitivity—Bleomycin—skin cancer	0.00158	0.00234	CcSEcCtD
Methyldopa—Cardiac disorder—Docetaxel—skin cancer	0.00157	0.00233	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Temozolomide—skin cancer	0.00156	0.00231	CcSEcCtD
Methyldopa—Constipation—Temozolomide—skin cancer	0.00155	0.00229	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—skin cancer	0.00155	0.44	CrCbGaD
Methyldopa—Asthenia—Bleomycin—skin cancer	0.00154	0.00228	CcSEcCtD
Methyldopa—Angiopathy—Docetaxel—skin cancer	0.00154	0.00227	CcSEcCtD
Methyldopa—Mediastinal disorder—Docetaxel—skin cancer	0.00153	0.00226	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00152	0.00225	CcSEcCtD
Methyldopa—Paraesthesia—Fluorouracil—skin cancer	0.0015	0.00222	CcSEcCtD
Methyldopa—Mental disorder—Docetaxel—skin cancer	0.00148	0.0022	CcSEcCtD
Methyldopa—Hypersensitivity—Dactinomycin—skin cancer	0.00147	0.00218	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00144	0.00213	CcSEcCtD
Methyldopa—Asthenia—Dactinomycin—skin cancer	0.00144	0.00212	CcSEcCtD
Methyldopa—Body temperature increased—Temozolomide—skin cancer	0.00143	0.00212	CcSEcCtD
Methyldopa—Diarrhoea—Dactinomycin—skin cancer	0.00137	0.00203	CcSEcCtD
Methyldopa—Vomiting—Bleomycin—skin cancer	0.00136	0.00202	CcSEcCtD
Methyldopa—Rash—Bleomycin—skin cancer	0.00135	0.002	CcSEcCtD
Methyldopa—Dermatitis—Bleomycin—skin cancer	0.00135	0.002	CcSEcCtD
Methyldopa—Hypersensitivity—Temozolomide—skin cancer	0.00133	0.00197	CcSEcCtD
Methyldopa—Leukopenia—Docetaxel—skin cancer	0.00132	0.00195	CcSEcCtD
Methyldopa—Body temperature increased—Fluorouracil—skin cancer	0.00132	0.00195	CcSEcCtD
Methyldopa—Asthenia—Temozolomide—skin cancer	0.0013	0.00192	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00128	0.00577	CbGpPWpGaD
Methyldopa—Nausea—Bleomycin—skin cancer	0.00127	0.00189	CcSEcCtD
Methyldopa—Vomiting—Dactinomycin—skin cancer	0.00127	0.00188	CcSEcCtD
Methyldopa—Rash—Dactinomycin—skin cancer	0.00126	0.00187	CcSEcCtD
Methyldopa—Myalgia—Docetaxel—skin cancer	0.00126	0.00186	CcSEcCtD
Methyldopa—Arthralgia—Docetaxel—skin cancer	0.00126	0.00186	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00125	0.00185	CcSEcCtD
Methyldopa—Diarrhoea—Temozolomide—skin cancer	0.00124	0.00183	CcSEcCtD
Methyldopa—Hypersensitivity—Fluorouracil—skin cancer	0.00123	0.00182	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—CDK4—skin cancer	0.00121	0.00545	CbGpPWpGaD
Methyldopa—Oedema—Docetaxel—skin cancer	0.0012	0.00178	CcSEcCtD
Methyldopa—Dizziness—Temozolomide—skin cancer	0.0012	0.00177	CcSEcCtD
Methyldopa—Infection—Docetaxel—skin cancer	0.0012	0.00177	CcSEcCtD
Methyldopa—Nausea—Dactinomycin—skin cancer	0.00119	0.00176	CcSEcCtD
Methyldopa—Nervous system disorder—Docetaxel—skin cancer	0.00118	0.00175	CcSEcCtD
Methyldopa—Thrombocytopenia—Docetaxel—skin cancer	0.00118	0.00174	CcSEcCtD
Methyldopa—Skin disorder—Docetaxel—skin cancer	0.00117	0.00173	CcSEcCtD
Methyldopa—ADRA2A—lymph node—skin cancer	0.00116	0.0118	CbGeAlD
Methyldopa—Vomiting—Temozolomide—skin cancer	0.00115	0.0017	CcSEcCtD
Methyldopa—Rash—Temozolomide—skin cancer	0.00114	0.00169	CcSEcCtD
Methyldopa—Diarrhoea—Fluorouracil—skin cancer	0.00114	0.00169	CcSEcCtD
Methyldopa—Dermatitis—Temozolomide—skin cancer	0.00114	0.00169	CcSEcCtD
Methyldopa—Headache—Temozolomide—skin cancer	0.00113	0.00168	CcSEcCtD
Methyldopa—Dizziness—Fluorouracil—skin cancer	0.0011	0.00163	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Docetaxel—skin cancer	0.0011	0.00162	CcSEcCtD
Methyldopa—Paraesthesia—Docetaxel—skin cancer	0.00108	0.0016	CcSEcCtD
Methyldopa—Nausea—Temozolomide—skin cancer	0.00108	0.00159	CcSEcCtD
Methyldopa—Vomiting—Fluorouracil—skin cancer	0.00106	0.00157	CcSEcCtD
Methyldopa—Rash—Fluorouracil—skin cancer	0.00105	0.00156	CcSEcCtD
Methyldopa—Dermatitis—Fluorouracil—skin cancer	0.00105	0.00155	CcSEcCtD
Methyldopa—Headache—Fluorouracil—skin cancer	0.00104	0.00155	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Docetaxel—skin cancer	0.00104	0.00154	CcSEcCtD
Methyldopa—Constipation—Docetaxel—skin cancer	0.00103	0.00152	CcSEcCtD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00101	0.00453	CbGpPWpGaD
Methyldopa—Nausea—Fluorouracil—skin cancer	0.000991	0.00147	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—BRAF—skin cancer	0.000955	0.0043	CbGpPWpGaD
Methyldopa—Body temperature increased—Docetaxel—skin cancer	0.000952	0.00141	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—PTCH2—skin cancer	0.00091	0.00409	CbGpPWpGaD
Methyldopa—Hypersensitivity—Docetaxel—skin cancer	0.000887	0.00131	CcSEcCtD
Methyldopa—DDC—Metabolism—PLIN2—skin cancer	0.000879	0.00395	CbGpPWpGaD
Methyldopa—Asthenia—Docetaxel—skin cancer	0.000864	0.00128	CcSEcCtD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000864	0.00388	CbGpPWpGaD
Methyldopa—Diarrhoea—Docetaxel—skin cancer	0.000824	0.00122	CcSEcCtD
Methyldopa—Dizziness—Docetaxel—skin cancer	0.000796	0.00118	CcSEcCtD
Methyldopa—COMT—Metabolism—PLIN2—skin cancer	0.00078	0.00351	CbGpPWpGaD
Methyldopa—Vomiting—Docetaxel—skin cancer	0.000765	0.00113	CcSEcCtD
Methyldopa—Rash—Docetaxel—skin cancer	0.000759	0.00112	CcSEcCtD
Methyldopa—Dermatitis—Docetaxel—skin cancer	0.000758	0.00112	CcSEcCtD
Methyldopa—Headache—Docetaxel—skin cancer	0.000754	0.00112	CcSEcCtD
Methyldopa—COMT—Neuronal System—BRAF—skin cancer	0.000732	0.00329	CbGpPWpGaD
Methyldopa—Nausea—Docetaxel—skin cancer	0.000715	0.00106	CcSEcCtD
Methyldopa—DDC—Metabolism—CSPG4—skin cancer	0.000708	0.00318	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000663	0.00298	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—MC1R—skin cancer	0.000658	0.00296	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CSPG4—skin cancer	0.000629	0.00283	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL6—skin cancer	0.000578	0.0026	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000568	0.00255	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RHOU—skin cancer	0.000565	0.00254	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—skin cancer	0.000515	0.00232	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ENO2—skin cancer	0.000482	0.00216	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—IL6—skin cancer	0.000472	0.00212	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SHH—skin cancer	0.000469	0.00211	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTCH2—skin cancer	0.000467	0.0021	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SMO—skin cancer	0.000444	0.002	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTCH1—skin cancer	0.000444	0.002	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—HRAS—skin cancer	0.000439	0.00197	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTGER4—skin cancer	0.000433	0.00194	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ENO2—skin cancer	0.000428	0.00192	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—MC1R—skin cancer	0.000372	0.00167	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MC1R—skin cancer	0.000338	0.00152	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—HRAS—skin cancer	0.000337	0.00151	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLIN2—skin cancer	0.00031	0.00139	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ERCC2—skin cancer	0.00028	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTCH2—skin cancer	0.000276	0.00124	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CSPG4—skin cancer	0.00025	0.00112	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ERCC2—skin cancer	0.000248	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTGER4—skin cancer	0.000244	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SHH—skin cancer	0.000241	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SMO—skin cancer	0.000228	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTCH1—skin cancer	0.000228	0.00103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTGER4—skin cancer	0.000222	0.000998	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLI2—skin cancer	0.000209	0.00094	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MC1R—skin cancer	0.000199	0.000896	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLI1—skin cancer	0.000197	0.000884	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SUFU—skin cancer	0.000186	0.000838	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO2—skin cancer	0.00017	0.000764	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—skin cancer	0.000168	0.000754	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—skin cancer	0.000149	0.000669	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SHH—skin cancer	0.000142	0.000639	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RASA1—skin cancer	0.000141	0.000635	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTCH1—skin cancer	0.000135	0.000606	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMO—skin cancer	0.000135	0.000606	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTGER4—skin cancer	0.000131	0.000589	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FOXO4—skin cancer	0.000116	0.000521	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—skin cancer	0.000114	0.000511	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ERCC2—skin cancer	9.87e-05	0.000444	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—skin cancer	9.77e-05	0.000439	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—skin cancer	8.69e-05	0.000391	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—skin cancer	8.31e-05	0.000374	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—skin cancer	7.74e-05	0.000348	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—skin cancer	6.52e-05	0.000293	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—skin cancer	6.13e-05	0.000275	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—skin cancer	5.92e-05	0.000266	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—skin cancer	5.61e-05	0.000252	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—skin cancer	4.77e-05	0.000214	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—skin cancer	4.56e-05	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—skin cancer	3.85e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—skin cancer	3.31e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—skin cancer	2.95e-05	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—skin cancer	2.82e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—skin cancer	2.7e-05	0.000121	CbGpPWpGaD
